Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties

Fig. 5

Shisa3 controls EGFR-TKI resistance via inhibition of FGFR/AKT/mTOR and cell cycle signaling. a. Volcano plot depicting a log transformation plot of the fold difference (x-axis) and the P-value (y-axis) of indicated genes between PC9-shShisa3 and PC9- shControl cells. b. Signaling pathways were enriched in the PC9-shShisa3 cells over the control cells by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis using a microarray. c. Western blots show AKT, mTOR, S6K and S6 and their phosphorylation signals in PC9/ER cells and PC9 cells with the indicated shisa3 expression. d. PC9/ER-control and PC9/ER-shisa3 cells were incubated with the following agents: gefitinib (0.5 μM), osimertinib (0.1 μM), BEZ235 (0.01 μM), or a combination of gefitinib/osimertinib and BEZ235. e. Flow-cytometric analysis of cell cycle distribution in PC9/ER-control and PC9/ER-shisa3 cells. f. The percentage of the cell population at G0/G1, S, and G2/M phases in PC9-shControl and PC9-shShisa3 cells. g. Effect of shisa3 expression on cell cycle-related proteins. h. PC9/ER-control and PC9/ER-shisa3 cells were incubated with the following agents: gefitinib (0.5 μM), osimertinib (0.1 μM), PD0332991 (12 μM), or a combination of gefitinib/osimertinib and PD0332991. d, e, f and h: n.s. p > 0.05; *p < 0.05; ***p < 0.0001

Back to article page